CAMBRIDGE, Mass.–(BUSINESS WIRE)–Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has named EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series. EB-003 was selected based on data analyses suggesting the molecule’s potential to be a first-in-class appro
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://mmpconnect.com/enveric-biosciences-selects-eb-003-as-lead-drug-candidate-from-evm301-series/?utm_source=rss&utm_medium=rss&utm_campaign=enveric-biosciences-selects-eb-003-as-lead-drug-candidate-from-evm301-series
- :has
- a
- addiction
- analyses
- and
- announced
- Anxiety
- AS
- based
- BE
- biotechnology
- business
- Business Wire
- candidate
- company
- Company’s
- connection
- CSS
- data
- dedicated
- depression
- Development
- disorders
- drug
- For
- from
- http
- HTTPS
- IT
- ITS
- jpg
- lead
- LINK
- marijuana
- Mass
- medical
- Medical Marijuana
- Named
- Nasdaq
- next-generation
- novel
- of
- on
- or
- plato
- Plato Data Intelligence
- PlatoData
- potential
- Program
- selected
- Series
- that
- The
- therapeutics
- to
- today
- treatment
- was
- Wire
- zephyrnet